Strategy

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and biotech ahead.

HEOR requires executive leaders who have both scientific and managerial acumen.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.

New technology is creating new opportunities but is also causing new complications.

In early phase trials innovative designs offer potential for improvements in efficiency and decision-making.

Veeva’s vice president of commercial strategy discusses how pharma companies streamlining their processes with a single goal in mind can improve their relationships with customers.

While challenges remain, AI is accelerating the process by enabling researchers to identify and design new drug candidates more quickly and efficiently with applications in target discovery, structure prediction, and drug optimization.

In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols.

With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Unleashed demand over the past year characterizes the M&A picture in pharma.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Why tapping the value generated for the next set of therapies is critical.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.

By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.

The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.

Three key components to scaling quickly—while maintaining purpose.

A value deficit and potential consumer value proposition.

A Harvard Business School Healthcare Alumni Association Q&A with Martin Gonzalez, Principal of Org and Leadership Development at Google.

Omnichannel marketing can help companies improve HCP engagement to facilitate the delivery of effective treatment to patients who desperately need and deserve it.

The Octave Bioscience CEO discusses leading the company through commercialization and expansion.

Atossa Therapeutics’ CEO discusses how the new draft guidance will change the way that many women receive their breast exam results.

Conferences, congresses, and the digital discussions kicked off by those events create a halo effect that amplifies scientific information more so than other scientific activities.

Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.